AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

SKYRIZI is the new option for psoriatic arthritis.

Policy

FDA Crackdown on JAK Drug Class Unwelcome News for Pharma Giants

Henceforth, all JAK-inhibiting drugs like AbbVie’s Rinvoq, Pfizer’s Xeljanz, and Lilly’s Olumiant, have been ordered to include a warning label on the medicine to be sold in the U.S.

September 2, 2021

4 min read

BioSpace Editorial Staff

Genetown

Biotech Company Driven by Cutting Edge Science and Patients, Not Ego

On June 26, Intellia announced the first-ever clinical data supporting the safety and efficacy of in vivo CRISPR genome editing in human patients.

August 30, 2021

5 min read

Heather McKenzie

Employer Resources

As Delta Variant Surges, More Biopharma Companies Mandate COVID-19 Vaccines

Fueled by the highly contagious delta variant, life science companies have issued policies on COVID-19 vaccines, including verbiage around exemptions or solutions for medical objections.

August 19, 2021

4 min read

Kate Goodwin

Deals

AbbVie’s Soliton Acquisition Hits a Snag as FTC Increases Scrutiny

AbbVie’s Allergan Aesthetics announced it was buying Soliton in a deal worth about $550 million. Now, the Federal Trade Commission has requested additional information about the deal.

August 11, 2021

2 min read

Mark Terry

AbbVie recently returned the rights of eye drug Ab

BioMidwest

PAbbVie Returns Eye Drug Abicipar Pegol Rights to Molecular Partners

AbbVie has terminated its license and collaboration deal with Molecular Partners for abicipar pegol, and returned all rights to the Swiss company. Here’s more about it.

August 9, 2021

3 min read

Mark Terry

Business

Mission and AbbVie Reach Second Milestone in Alzheimer’s, Parkinson’s Drug Research

Mission Therapeutics and AbbVie announced their DUB inhibitor collaboration back in 2018.

August 9, 2021

2 min read

Brandon May

Courtesy of Smith Collection/Gado/Getty Images

Policy

AbbVie’s Humira Sales Drop Internationally from Biosimilar Competition, but Not in the U.S.

Biosimilars have gained traction in Europe, but not in the U.S. AbbVie’s Humira is often made as an example of how companies are using legal tactics to delay biosimilar competition.

August 4, 2021

3 min read

Mark Terry

AbbVie_© AbbVie Inc. All rights reserved.

Drug Development

AbbVie Enjoys Strong Second Quarter as Rinvoq Gears Up to Succeed Humira

The company saw global net revenue of $13.9 billion during the second quarter, an increase of 33.9%. Sales were primarily driven by its immunology portfolio, which generated $6.12 billion.

August 2, 2021

3 min read

Alex Keown